Prediction of chemotherapeutic response in ovarian cancer with DNA microarray expression profiling.

Ovarian carcinoma is a leading cause of gynecologic cancer death in women. Despite treatment, a large number of women with ovarian cancer eventually relapse and die of the disease. Hence, recurrent ovarian cancer continues to be a therapeutic dilemma, possibly a result of the emergence of drug resistance during relapse. Recent advances in expression genomics enable global transcript analysis that leads to molecular classification of cancers and prediction of outcome and treatment response. We did a cDNA microarray examination of the expression profiles of eight primary ovarian cancers stratified into two groups based on their chemotherapeutic response. We applied a voice-speech-pattern recognition algorithm for microarray data analysis and were able to model and predict the response of these patients to chemotherapy from their expression profiles. Hence, gene expression profiling by means of DNA microarray may be applied diagnostically for predicting treatment response in ovarian cancer.

[1]  H. Rubin.  Synergistic mechanisms in carcinogenesis by polycyclic aromatic hydrocarbons and by tobacco smoke: a bio-historical perspective with updates. , 2001, Carcinogenesis.

[2]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[3]  R. Ozols,et al.  Mechanisms of drug resistance in ovarian cancer , 2010, Cancer.

[4]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[5]  R. Ozols.  Management of advanced ovarian cancer consensus summary. Advanced Ovarian Cancer Consensus Faculty. , 2000, Seminars in oncology.

[6]  M. Bittner,et al.  Monitoring the expression profiles of doxorubicin-induced and doxorubicin-resistant cancer cells by cDNA microarray. , 2000, Cancer research.

[7]  I. Pastan,et al.  Function and regulation of the human multidrug resistance gene. , 1993, Advances in cancer research.

[8]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[9]  R. Agarwal,et al.  Ovarian cancer: strategies for overcoming resistance to chemotherapy , 2003, Nature Reviews Cancer.

[10]  J. Shepherd.  Revised FIGO staging for gynaecological cancer , 1989, British journal of obstetrics and gynaecology.

[11]  Yudong D. He,et al.  A Gene-Expression Signature as a Predictor of Survival in Breast Cancer , 2002 .

[12]  E. Dougherty,et al.  Gene-expression profiles in hereditary breast cancer. , 2001, The New England journal of medicine.

[13]  D J Lockhart,et al.  Arrays of arrays for high-throughput gene expression profiling. , 2001, Genome research.

[14]  E. Clayton.  Ethical, legal, and social implications of genomic medicine. , 2003, The New England journal of medicine.

[15]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[16]  J. Diebold.  Molecular genetics of ovarian carcinomas. , 1999, Histology and Histopathology.

[17]  J. Mesirov,et al.  Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. , 1999, Science.

[18]  Ahmedin Jemal,et al.  Cancer Statistics, 2002 , 2002, CA: a cancer journal for clinicians.

[19]  Michael Fraser,et al.  Role of X-linked inhibitor of apoptosis protein in chemoresistance in ovarian cancer: possible involvement of the phosphoinositide-3 kinase/Akt pathway. , 2002, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[20]  H. Rubin.  Selected cell and selective microenvironment in neoplastic development. , 2001, Cancer research.

[21]  R. Wooster,et al.  Breast and ovarian cancer. , 2003, The New England journal of medicine.

[22]  David E. Misek,et al.  Gene-expression profiles predict survival of patients with lung adenocarcinoma , 2002, Nature Medicine.

[23]  D. Lockhart,et al.  Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[24]  J. Downing,et al.  Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. , 2002, Cancer cell.

[25]  L. Goodell,et al.  Administration of a phorbol ester to patients with hematological malignancies: preliminary results from a phase I clinical trial of 12-O-tetradecanoylphorbol-13-acetate. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.